Problems experienced by community pharmacists delivering opioid substitution treatment in New South Wales and Victoria, Australia

Addiction

Volumn 105, Issue 2, 2010, Pages 335-342

  Winstock, Adam R ^a,b,c   Lea, Toby ^a   Sheridan, Janie ^d  

^a Drug Health Services   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Buprenorphine; Community pharmacy; Methadone; Opioid substitution therapy; Prescriber; Problems; Termination

Indexed keywords

BUPRENORPHINE; METHADONE; NARCOTIC ANALGESIC AGENT;

ARTICLE; AUSTRALIA; CROSS-SECTIONAL STUDY; ECONOMICS; FEMALE; HUMAN; HUMAN RELATION; MALE; OPIATE ADDICTION; PATIENT ABANDONMENT; PATIENT COMPLIANCE; PHARMACY; PUBLIC RELATIONS; QUESTIONNAIRE; STATISTICS;

ANALGESICS, OPIOID; BUPRENORPHINE; COMMUNITY PHARMACY SERVICES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INTERPROFESSIONAL RELATIONS; MALE; MEDICATION ADHERENCE; METHADONE; NEW SOUTH WALES; OPIOID-RELATED DISORDERS; PROFESSIONAL-PATIENT RELATIONS; QUESTIONNAIRES; REFUSAL TO TREAT; VICTORIA;

EID: 74249106218     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2009.02774.x     Document Type: Article

References (26)

1. Gossop M., Grant M. A six country survey of the content and structure of heroin treatment programmes using methadone. Br J Addict 1991 86 : 1151 1160.
2. McCormick I. R. N., Bryant L. J. M., Sheridan J., Gonzalez J. New Zealand community pharmacist attitudes toward treating opioid dependent clients. Drug Educ Prev Policy 2006 13 : 363 375.
3. Vignau J., Brunelle E. Differences between general practitioner- and addiction centre-prescribed buprenorphine substitution therapy in France. Eur Addict Res 1998 4 : 24 8.
4. Lawrinson P., Roche A., Terao H., Le P.-P. Dispensing opioid substitution treatment: practices, attitudes and intentions of community-based pharmacists. Drug Alcohol Rev 2008 27 : 47 53.
5. Matheson C., Bond C. M., Pitcairn J. Community pharmacy services for drug misusers in Scotland: what difference does 5 years make? Addiction 2002 97 : 1405 1411.
6. Sheridan J., Lovell S., Turnbull P., Parsons J., Stimson G., Strang J. Pharmacy-based needle exchange (PBNX) schemes in South East England: a survey of service providers. Addiction 2000 95 : 1551 1560.
7. Matheson C., Bond C. M., Mollison J. Attitudinal factors associated with community pharmacists' involvement in services for drug misusers. Addiction 1999 94 : 1349 1359.
8. Sheridan J., Cronin F. Supervised self-administration of methadone at community pharmacies: the introduction of a new service. Pharm J 2002 268 : 471 474.
9. Sheridan J., Strang J., Taylor C., Barber N. HIV prevention and drug treatment services for drug misusers: a national study of community pharmacists' attitudes and their involvement in service specific training. Addiction 1997 92 : 1737 1748.
10. Australian Institute of Health and Welfare (AIHW). Alcohol and Other Drug Treatment Services in Australia 2005-2006: Report on the National Minimum Data Set. Canberra : AIHW 2007.
11. Victorian Department of Human Services. Policy for Maintenance Pharmacotherapy for Opioid Dependence. Melbourne : Victorian Department of Human Services 2006.
12. Treloar C., Fraser S., Valentine K. Valuing methadone takeaway doses: the contribution of service user perspectives to policy and practice. Drug Educ Prev Policy 2007 14 : 61 74.
13. Winstock A., Lea T., Molan J. New South Wales community pharmacy practice survey. SWAT Report 2. NDARC Technical Report no. 297. Sydney: National Drug and Alcohol Research Centre 2008.
14. Winstock A. R., Lea T., Sheridan J. What is diversion of supervised buprenorphine and how common is it? J Addict Dis 2009 28 : 269 278.
15. Ward J., Mattick R. P., Hall W. The effectiveness of methadone maintenance treatment: an overview. Drug Alcohol Rev 1994 13 : 327 336.
16. Ezard N., Lintzeris N., Odgers P., Koutroulis G., Muhleisen P., Stowe A. et al. An evaluation of community methadone services in Victoria, Australia: results of a client survey. Drug Alcohol Rev 1999 18 : 417 423.
17. Holt T., Ritter A., Swan A., Pahoki S. Australian Treatment Outcome Study (ATOS): Heroin. Melbourne : Turning Point Alcohol & Drug Centre 2002.
18. Winstock A. R., Lea T., Madden A., Bath N. Knowledge about buprenorphine and methadone among those receiving treatment for opioid dependence. Drug Educ Prev Policy 2008 15 : 395 409.
19. Larance B., Degenhardt L., Mattick R. P., O'Brien S., Lintzeris N., Bell J. et al. The diversion and injection of the pharmaceutical opioids used in opioid substitution treatment: findings from the Australian post-marketing surveillance studies of buprenorphine-naloxone. NDARC Technical Report no. 302. Sydney : National Drug and Alcohol Research Centre 2009.
20. Lintzeris N., Pritchard E., Sciacchitano L. Investigation of Methadone Dosing in Victoria: Factors Influencing Dosing Levels. Melbourne : Turning Point Alcohol and Drug Centre 2007.
21. Gossop M., Marsden J., Stewart D., Kidd T. The National Treatment Outcome Research Study (NTORS): 4-5 year follow-up results. Addiction 2003 98 : 291 303.
22. Ross J., Teesson M., Darke S., Lynskey M., Ali R., Ritter A. et al. The characteristics of heroin users entering treatment: findings from the Australian Treatment Outcome Study (ATOS). Drug Alcohol Rev 2005 24 : 411 418. (Pubitemid 43024040)
23. Muhleisen P. Maintenance treatment for opioid dependence - who should pay? Aust Pharm 2002 21 : 414 418.
24. Darke S., Ross J., Hall W. Prevalence and correlates of the injection of methadone syrup in Sydney, Australia. Drug Alcohol Depend 1996 43 : 191 198. (Pubitemid 27046188)
25. Winstock A. R., Bell J. Clinical Guidelines Assessing Suitability for Unsupervised Medication Doses in the Treatment of Opioid Dependency. Sydney : Royal Australasian College of Physicians and Australasian Chapter of Addiction Medicine 2006.
26. Winstock A. R., Molan J. The Patient Journey Kit 1: Transfer of Stable Public Clinic Opioid-Dependent Patients to GP Prescribers. Sydney : State-wide Advisory Team (SWAT), NSW Department of Health 2007. Available at: http://www.health.nsw.gov.au/resources/drugs/patientjourneykit1-pdf.asp (accessed 8 August 2009).